This clinical trial is focused on studying a type of cancer called Chronic Lymphocytic Leukemia (CLL), which affects the blood and bone marrow. The study is investigating the use of a treatment called Panzyga, which is a solution containing human normal immunoglobulin. This treatment is being compared to a placebo to see if it can help prevent infections in patients with CLL who have a weakened immune system, a condition known as secondary immunodeficiency. The goal is to determine if Panzyga can effectively reduce the risk of infections in these patients.

During the study, participants will receive either Panzyga or a placebo through an intravenous infusion, which means the solution is given directly into a vein. The study is designed to be double-blind, meaning neither the patients nor the doctors will know who is receiving the actual treatment or the placebo. This helps ensure that the results are unbiased. The study will last for a period of time, during which the safety and effectiveness of Panzyga in preventing infections will be closely monitored.

The main purpose of this study is to demonstrate the benefit of using Panzyga as a primary infection prevention method in patients with CLL who are undergoing treatment for their cancer. By comparing the occurrence of infections in patients receiving Panzyga versus those receiving a placebo, researchers hope to gather important information about the potential advantages of this treatment in managing the risk of infections in CLL patients with a compromised immune system.